Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Donor Lymphocyte Infusion (DLI) for Mixed Chimerism 6 Months after T Cell Depleted Allogeneic Stem Cell Transplantation (TCD alloSCT) May Prevent Relapse.

Erik W.A. Marijt, MD, PhD, Peter A. Von Dem Borne, MD PhD, Renee M.Y. Barge, MD PhD, Piette P. Deutz, M. Floor Beaumont, C.W.J. Ingrid Starrenburg, Willem E. Fibbe, MD PhD, Roelof Willemze, MD PhD, J.H. Frederik Falkenburg, MD PhD

Blood (2006) 108 (11): 3674.

https://doi.org/10.1182/blood.V108.11.3674.3674

Published: 2006

Journal Articles

Adoptive Immunotherapy with Donor Lymphocyte Infusions after T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia.

Renee M.Y. Barge, MD, PhD, Eva Steel, MD, Ingrid Starrenburg, Floor Beaumont, Willem M. Smit, MD, PhD, Martyn Ronald Schaafsma, MD, PhD, Ward Posthuma, MD, PhD, Willem E. Fibbe, MD, PhD, Frederik Falkenburg, MD, PhD, Roelof Willemze, MD, PhD

Blood (2005) 106 (11): 2014.

https://doi.org/10.1182/blood.V106.11.2014.2014

Published: 2005

Journal Articles

A Two Step Nonmyeloablative Allogeneic Transplantation Protocol Using In Vitro T-Cell Depleted Mobilized Stem Cells Followed by Donor Lymphocyte Infusions in Patients with Advanced CLL.

Renee M.Y. Barge, MD, PhD, Mels Hoogendoorn, MD, Erik W.A. Marijt, MD, PhD, Floor Beaumont, Ingrid Starrenburg, Willem Smit, MD, PhD, Ward Posthuma, MD, PhD, Willem E. Fibbe, MD, PhD, Frederik Falkenburg, MD, PhD, Roelof Willemze, MD, PhD

Blood (2005) 106 (11): 5396.

https://doi.org/10.1182/blood.V106.11.5396.5396

Published: 2005

Journal Articles

HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.

Blood (2005) 106 (11): 424.

https://doi.org/10.1182/blood.V106.11.424.424

Published: 2005

Journal Articles

Improved Long Term Survival with Minimal GVHD after Myeloablative Unrelated Donor Stem Cell Transplantation Using In Vitro and In Vivo T Cell Depletion with CAMPATH-1H.

Peter A. von dem Borne, Floor Beaumont, Ingrid Starrenburg, Machteld A. Oudshoorn, Geoff Hale, J.H. Frederik Falkenburg, Willem E. Fibbe, Roel Willemze, Renee M.Y. Barge

Blood (2004) 104 (11): 2761.

https://doi.org/10.1182/blood.V104.11.2761.2761

Published: 2004

NARROW

Donor Lymphocyte Infusion (DLI) for Mixed Chimerism 6 Months after T Cell Depleted Allogeneic Stem Cell Transplantation (TCD alloSCT) May Prevent Relapse.

Adoptive Immunotherapy with Donor Lymphocyte Infusions after T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia.

A Two Step Nonmyeloablative Allogeneic Transplantation Protocol Using In Vitro T-Cell Depleted Mobilized Stem Cells Followed by Donor Lymphocyte Infusions in Patients with Advanced CLL.

HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.

Improved Long Term Survival with Minimal GVHD after Myeloablative Unrelated Donor Stem Cell Transplantation Using In Vitro and In Vivo T Cell Depletion with CAMPATH-1H.

Email alerts

ASH Publications

American Society of Hematology

Donor Lymphocyte Infusion (DLI) for Mixed Chimerism 6 Months after T Cell Depleted Allogeneic Stem Cell Transplantation (TCD alloSCT) May Prevent Relapse.

Adoptive Immunotherapy with Donor Lymphocyte Infusions after T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia.

A Two Step Nonmyeloablative Allogeneic Transplantation Protocol Using In Vitro T-Cell Depleted Mobilized Stem Cells Followed by Donor Lymphocyte Infusions in Patients with Advanced CLL.

HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.

Improved Long Term Survival with Minimal GVHD after Myeloablative Unrelated Donor Stem Cell Transplantation Using In Vitro and In Vivo T Cell Depletion with CAMPATH-1H.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only